Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Hypothetical protein | 0.0726 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0819 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0406 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0506 | 0.2407 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0819 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0819 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0819 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0819 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0819 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0819 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0819 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0819 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0819 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0819 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0819 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0819 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0819 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0406 | 0 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0819 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0726 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0819 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0819 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0819 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0413 | 0.0151 | 0.0151 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0819 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0819 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0506 | 0.2407 | 0.2407 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0819 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0819 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Cytotoxicity (functional) | = 0 % | Tested for the cytotoxicity of the compound against JM cells at 100 microM in an MTT assay | ChEMBL. | No reference |
Cytotoxicity (functional) | = 32 % | Tested for the cytotoxicity of the compound against JM cells at 100 microM in an MTT assay | ChEMBL. | No reference |
Inhibition (functional) | = 20 % | Tested for antiviral microM; Activity expressed as % inhibition of syncytium | ChEMBL. | No reference |
Inhibition (functional) | = 27 % | Tested for antiviral microM; Activity expressed as % inhibition of syncytium | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.